KEYTRUDA Granted Breakthrough Therapy Designation by FDA For Lung Cancer Treatment
News
Merck’s KEYTRUDA (pembrolizumab), has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with Epidermal Growth Factor Receptor (EGFR) mutation-negative, and Anaplastic ... Read more